During the past decade, Institut Universitaire de Cardiologie et de Pneumologie de Québec conducted 176 clinical trials. In the 10-year time frame, 176 clinical trials started and 70 clinical trials were completed, i.e. on average, 39.8% percent of trials that started reached the finish line to date. In the past 5 years, 57 clinical trials started and 30 clinical trials were completed. i.e. 52.6% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Institut Universitaire de Cardiologie et de Pneumologie de Québec" #1 sponsor was "Laval University" with 88 trials, followed by "Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec" with 22 trials sponsored, "Boehringer Ingelheim" with 15 trials sponsored, "Medtronic Cardiac Rhythm and Heart Failure" with 15 trials sponsored and "Abbott Medical Devices" with 15 trials sponsored. Other sponsors include 204 different institutions and companies that sponsored additional 119 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Institut Universitaire de Cardiologie et de Pneumologie de Québec" #1 collaborator was "Canadian Institutes of Health Research (CIHR)" with 37 trials as a collaborator, "National Heart, Lung, and Blood Institute (NHLBI)" with 12 trials as a collaborator, "Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec" with 7 trials as a collaborator, "Medtronic" with 7 trials as a collaborator and "AstraZeneca" with 6 trials as a collaborator. Other collaborators include 219 different institutions and companies that were collaborators in the rest 161 trials.

According to Clinical.Site data, the most researched conditions in "Institut Universitaire de Cardiologie et de Pneumologie de Québec" are "Atrial Fibrillation" (22 trials), "Asthma" (21 trials), "Heart Failure" (21 trials), "Aortic Valve Stenosis" (15 trials) and "Coronary Artery Disease" (15 trials). Many other conditions were trialed in "Institut Universitaire de Cardiologie et de Pneumologie de Québec" in a lesser frequency.

Most popular intervention types in "Institut Universitaire de Cardiologie et de Pneumologie de Québec" are "Drug" (144 trials), "Device" (116 trials), "Other" (50 trials), "Procedure" (36 trials) and "Behavioral" (10 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (53 trials), "placebo" (7 trials), "Empagliflozin" (4 trials), "Cisplatin" (3 trials) and "FreeO2" (3 trials). Other intervention names were less common.

The vast majority of trials in "Institut Universitaire de Cardiologie et de Pneumologie de Québec" are 352 trials for "All" genders, 6 trials for "Female" genders and 5 trials for "Male" genders.

Currently, there are 114 active trials in "Institut Universitaire de Cardiologie et de Pneumologie de Québec". 8 are not yet recruiting, 62 are recruiting, 41 are Active, not recruiting, and 3 are Enrolling by invitation. In total, there were 178 completed trials in Institut Universitaire de Cardiologie et de Pneumologie de Québec, 2 suspended trials, and 32 terminated clinical trials to date.

Out of the total trials that were conducted in Institut Universitaire de Cardiologie et de Pneumologie de Québec, 9 "Phase 1" clinical trials were conducted, 48 "Phase 2" clinical trials and 77 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 27 trials, and there were also 158 trials that are defined as “Not Applicable".